Metraipolis › archive › dc_088caecf3065
Design and immunogenicity of a quadrivalent mRNA vaccine targeting HSV-2 with comparative evaluation of co-formulated and admixed formulations — Europe PMC PMID:41425559
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41425559
- DOI
- 10.3389/fimmu.2025.1712691
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T21:48:17.971Z
- SHA-256 of the archived text
e805b4707e83e7fb79c7d0afceb29e00bae3d9230ff82fc0548b279bb26f2894- Stable URL of this page
https://metraipolis.com/documento/dc_088caecf3065
How to cite
Design and immunogenicity of a quadrivalent mRNA vaccine targeting HSV-2 with comparative evaluation of co-formulated and admixed formulations — Europe PMC PMID:41425559 — Europe PMC (en), https://europepmc.org/article/MED/41425559 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_088caecf3065 (Metraipolis archive dc_088caecf3065, sha256 e805b4707e83e7fb79c7d0afceb29e00bae3d9230ff82fc0548b279bb26f2894)
BibTeX
@misc{dc088caecf3065,
title = {Design and immunogenicity of a quadrivalent mRNA vaccine targeting HSV-2 with comparative evaluation of co-formulated and admixed formulations — Europe PMC PMID:41425559},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41425559},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_088caecf3065; sha256 e805b4707e83e7fb79c7d0afceb29e00bae3d9230ff82fc0548b279bb26f2894},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41425559. Agents can read the archived copy with the MCP tool read_document.